Abstract:4,4‐Diallyl curcumin bis(2,2‐hydroxymethyl)propanoate, also known as 35e, displayed significant antilipid accumulation and antifibrotic effects in two complementary mice models. Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) that causes severe liver damage, fibrosis, and scarring. Despite its potential to progress to cirrhosis or hepatic failure, approved drugs or treatments are currently unavailable. We developed 4,4‐diallyl curcumin bis(2,2‐hydroxymethyl)propanoate, also known as 35e, which induces upregulation of mitochondrial proteins including carnitine palmitoyltransferase I (CPT‐I), carnitine palmitoyltransferase II, heat shock protein 60, and translocase of the outer mitochondrial membrane 20. Among these proteins, the upregulated expression of CPT‐I was most prominent. CPT‐I plays a crucial role in transporting carnitine across the mitochondrial inner membrane, thereby initiating mitochondrial β‐oxidation of fatty acids. Given recent research showing that CPT‐I activation could be a viable pathway for NASH treatment, we hypothesized that 35e could serve as a potential agent for treating NASH. The efficacy of 35e in treating NASH was evaluated in methionine‐ and choline‐deficient (MCD) diet‐ and Western diet (WD)‐induced models that mimic human NASH. In the MCD diet‐induced model, both short‐term (2 weeks) and long‐term (7 weeks) treatment with 35e effectively regulated elevated serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) concentrations and histological inflammation. However, the antisteatotic effect of 35e was obtained only in the short‐term treatment group. As a comparative compound in the MCD diet‐induced model, curcumin treatment did not produce significant regulatory effects on the liver triglyceride/total cholesterol, serum ALT/AST, or hepatic steatosis. In the WD‐induced model, 35e ameliorated hepatic steatosis and hepatic inflammation, while increasing serum AST and hepatic lipid content. A decrease in epididymal adipose tissue weight and serum free fatty acid concentration suggested that 35e may promote lipid metabolism or impede lipid accumulation. Overall, 35e displayed significant antilipid accumulation and antifibrotic effects in the two complementary mice models. The development of new curcumin derivatives with the ability to induce CPT‐I upregulation could further underscore their efficacy as anti‐NASH agents.

Curcumin attenuates non-alcohol fatty liver disease by inhibiting 17β-hydroxysteroid dehydrogenase 2

Curcumin prevents high-fat diet-induced hepatic steatosis in ApoE−/− mice by improving intestinal barrier function and reducing endotoxin and liver TLR4/NF-κB inflammation

Curcumin protects against high-fat diet-induced non-alcoholic simple fatty liver by inhibiting intestinal and hepatic NPC1L1 expression via down-regulation of SREBP-2/HNF1α pathway in hamsters

Curcumin alleviates hepatic steatosis by improving mitochondrial function in postnatal overfed rats and fatty L02 cells through the SIRT3 pathway

Effects of curcumin on non-alcoholic fatty liver disease: a scientific metrogy study

Steatosis induced by nonylphenol in HepG2 cells and the intervention effect of curcumin

Curcumin-Rich Diet Mitigates Non-Alcoholic Fatty Liver Disease (NAFLD) by Attenuating Fat Accumulation and Improving Insulin Sensitivity in Aged Female Mice under Nutritional Stress

Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats

Curcumol ameliorates alcohol and high-fat diet-induced fatty liver disease via modulation of the Ceruloplasmin/iron overload/mtDNA signaling pathway

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Effect of Curcumin on Rat Hepatic Fibrosis Induced by Carbon Tetrachoride

Protective role of curcumin in disease progression from non-alcoholic fatty liver disease to hepatocellular carcinoma: a meta-analysis

Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling

Diet Polyphenol Curcumin Stimulates Hepatic Fgf21 Production and Restores Its Sensitivity in High-Fat-Diet-Fed Male Mice.

Curcumin alleviates lipid deposition in hepatocytes through miR-3666/ AMPK axis regulation

1H-NMR and MS Based Metabolomics Study of the Intervention Effect of Curcumin on Hyperlipidemia Mice Induced by High-Fat Diet

Curcumol Suppresses CCF-Mediated Hepatocyte Senescence Through Blocking LC3B–Lamin B1 Interaction in Alcoholic Fatty Liver Disease

4,4‐Diallyl curcumin bis(2,2‐hydroxymethyl)propanoate ameliorates nonalcoholic steatohepatitis in methionine‐choline‐deficient diet and Western diet mouse models

Curcumin Improved Glucose Intolerance, Renal Injury, and Nonalcoholic Fatty Liver Disease and Decreased Chromium Loss through Urine in Obese Mice

Curcumin Attenuates on Carbon Tetrachloride-Induced Acute Liver Injury in Mice via Modulation of the Nrf2/HO-1 and TGF-β1/Smad3 Pathway

Curcumin exerts a protective effect against obesity and liver injury induced by an atherogenic diet